The World Health Organization issued conditional recommendations in 2026 endorsing doxy-PEP for men who have sex with men (MSM) and transgender women (TGW), coupled with explicit provisions to monitor antimicrobial resistance (AMR). The guidance represents the first global antibiotic prophylaxis recommendation for bacterial sexually transmitted infections (STIs). The authors reported that doxy-PEP reduced chlamydia and syphilis by roughly 70%–85% in trial populations and produced variable reductions in gonorrhea tied to local tetracycline resistance.
Bacterial STI incidence rose globally across much of the prior decade, driving interest in prevention strategies. Doxy-PEP is a single 200 mg dose taken within 72 hours after condomless sex. Trials in MSM/TGW, including people living with HIV and those on HIV PrEP, demonstrated substantial reductions in syphilis and chlamydia, with more mixed results for gonorrhea. The authors noted that doxycycline has activity against the most prevalent bacterial STI pathogens: Treponema pallidum, Chlamydia trachomatis, and Neisseria gonorrhoeae.
Resistance dynamics differ by pathogen. No acquired doxycycline resistance has been observed in Treponema pallidum or Chlamydia trachomatis in clinical settings; laboratory work suggests evolutionary barriers for T. pallidum. In contrast, Neisseria gonorrhoeae readily develops tetracycline resistance. Some regions already report tetracycline resistance exceeding 80%. The DOXYVAC study provided evidence of selection for the plasmid-borne tetM determinant. Investigators observed increasing phenotypic resistance among doxy-PEP users in Seattle and rising tetM prevalence in the US. The study team linked declining doxy-PEP efficacy against gonorrhea to increasing tetM prevalence. The net effect described is an initial reduction in gonorrhea prevalence in settings with low starting resistance, followed by selection and spread of resistant strains that can restore prevalence toward prior levels.
As STI prevalence declines under doxy-PEP use, the benefit per dose—measured in infections averted—shrinks. The number needed to treat to prevent a single infection increases. At the same time, if AMR translates into clinical problems like treatment failures, the AMR externality per dose grows. Those using doxy-PEP accrue immediate reductions in infections and related benefits; future patients and health systems may bear the costs of harder-to-treat infections. The authors emphasized that these shifting economics will vary by global setting, baseline resistance levels, sexual networks driving transmission, and local burdens of bacterial disease.
Attribution is complex. Surveillance capacity varies widely. Pre-existing temporal trends in STI incidence and AMR complicate causal inference. Uptake of doxy-PEP is heterogeneous across populations and regions, and surveillance systems may not capture the exposures needed to link policy changes to epidemiologic shifts. The authors pointed to problems around study design choices, data sources, eligibility criteria, and governance mechanisms that must be resolved to make transparent decisions about modifying recommendations.
Doxycycline exerts ecological pressure beyond target STIs. Among doxy-PEP users, colonization with Staphylococcus aureus fell, but those who remained colonized had higher rates of tetracycline-resistant S. aureus. Analysis of gut microbiomes from a DoxyPEP trial showed minimal compositional shifts yet a clear expansion and increased expression of tetracycline resistance genes over six months, with a dose–response pattern. A separate study of 100 mg daily doxycycline for 56 days reported persistent skin microbiome changes lasting beyond 200 days. The clinical consequences of microbiome shifts and increased resistance gene prevalence remain incompletely understood.
The authors argued that doxy-PEP should be governed as an adaptive intervention subject to periodic, transparent review using predefined criteria. They advocated expanding surveillance capacity for disease incidence and AMR and designing studies capable of distinguishing doxy-PEP effects from background trends. Monitoring should include pathogen-specific resistance markers (for example, tetM in Neisseria gonorrhoeae), phenotypic resistance, and bystander organism surveillance, as well as patient-centered outcomes such as anxiety, clinic visits avoided, and STI complications averted.
Policy choices must be context-specific. In settings with high baseline gonorrhea tetracycline resistance or different transmission networks (for example, heterosexual-driven syphilis epidemics), the balance of benefits and harms may differ from trial settings. Where surveillance infrastructure is insufficient, building or expanding systems adds cost and complexity to decision-making. The authors noted that intermittent individual reassessment of doxy-PEP use—as recommended by some national guidelines—may be reasonable, but that population-level thresholds and governance arrangements need specification.
Key unknowns remain. The efficacy of doxy-PEP in cisgender women is not established; a trial in Kenyan cisgender women did not show significant STI reduction. The magnitude and clinical impact of AMR selection in STIs and bystander organisms are incompletely defined. The authors also emphasized methodological gaps: how to attribute epidemiologic changes to doxy-PEP, what surveillance metrics to use, which thresholds should trigger guideline revision, and how governance should balance immediate individual benefits against potential future AMR costs. Those are concrete questions needing predefined decision rules, enhanced surveillance, and transparent review processes before guidelines are revisited.